drugset / Trial / NCT07035405
Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)
Phase 3
Not yet recruiting
7500 enrolled
Beijing Tiantan Hospital
Shenzhen Medical Academy of Research and Translation · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The role of colchicine in the secondary prevention of ischemic stroke has not been determinded. This multicenter, randomized, double-blind, placebo-controlled, event-driven clinical trial of CHANCE-3 EX was aimed to assess the efficacy and safety of low-dose colchicine versus placebo on reducing the risk of recurrent ischemic stroke, myocardial infarction and vascular death in patients with minor-to-moderate ischemic stroke.
Timeline
- Start
- 2025-07-04
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Colchicine | Small molecule | 0.5 mg | Oral |